Epitranscriptional regulation of cardiovascular development and disease

Journal of Physiology

Volumn 593, Issue 8, 2015, Pages 1799-1808

  Dorn, Gerald W ^a   Matkovich, Scot J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE PROTEIN; BRG1 PROTEIN; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 143; MICRORNA 21; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; POLYCOMB REPRESSIVE COMPLEX 2; POTASSIUM CHANNEL KCNQ1; RNA INDUCED SILENCING COMPLEX;

ARTICLE; CARDIOVASCULAR DISEASE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA SEQUENCE; EMBRYO DEVELOPMENT; EPIGENETICS; EPITRANSCRIPTIONAL REGULATION; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION REGULATION; HEART DEVELOPMENT; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEMODYNAMIC STRESS; HISTONE METHYLATION; HUMAN; HUMAN GENOME; INTRACELLULAR SIGNALING; NEGATIVE FEEDBACK; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RNA SPLICING; RNA STRUCTURE; RNA TRANSCRIPTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; CARDIOVASCULAR SYSTEM; DNA METHYLATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PATHOLOGY;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MICRORNAS; TRANSCRIPTION, GENETIC;

EID: 84927692252     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.283234     Document Type: Article

References (65)

1. Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE & Haldar SM (2013). BET bromodomains mediate transcriptional pause release in heart failure. Cell 154, 569-582.
2. Arai M, Otsu K, MacLennan DH & Periasamy M (1992). Regulation of sarcoplasmic reticulum gene expression during cardiac and skeletal muscle development. Am J Physiol Cell Physiol 262, C614-C620.
3. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF & Tewari M (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108, 5003-5008.
4. Bang C, Batkai S, Dangwal S, Gupta SK, Foinquinos A, Holzmann A, Just A, Remke J, Zimmer K, Zeug A, Ponimaskin E, Schmiedl A, Yin X, Mayr M, Halder R, Fischer A, Engelhardt S, Wei Y, Schober A, Fiedler J & Thum T (2014). Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 124, 2136-2146.
5. Bauters C, Kumarswamy R, Holzmann A, Bretthauer J, Anker SD, Pinet F & Thum T (2013). Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 168, 1837-1840.
6. Bernstein BE, Meissner A & Lander ES (2007). The mammalian epigenome. Cell 128, 669-681.
7. Bu D, Yu K, Sun S, Xie C, Skogerbø G, Miao R, Xiao H, Liao Q, Luo H, Zhao G, Zhao H, Liu Z, Liu C, Chen R & Zhao Y (2012). NONCODE v3.0: integrative annotation of long noncoding RNAs. Nucleic Acids Res 40, D210-D215.
8. Chi SW, Hannon GJ & Darnell RB (2012). An alternative mode of microRNA target recognition. Nat Struct Mol Biol 19, 321-327.
9. Chien KR, Knowlton KU, Zhu H & Chien S (1991). Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 5, 3037-3046.
10. Condorelli G, Latronico MV & Cavarretta E (2014). microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 63, 2177-2187.
11. ENCODE Project Consortium (2012). An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74.
12. Cripps RM & Olson EN (2002). Control of cardiac development by an evolutionarily conserved transcriptional network. Dev Biol 246, 14-28.
13. Denzler R, Agarwal V, Stefano J, Bartel DP & Stoffel M (2014). Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell 54, 766-776.
14. Devaux Y, Mueller M, Haaf P, Goretti E, Twerenbold R, Zangrando J, Vausort M, Reichlin T, Wildi K, Moehring B, Wagner DR & Mueller C (2013). Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med (in press; DOI: 10.1111/joim.12183).
15. Dorn GW 2nd (2007). The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49, 962-970.
16. Dorn GW 2nd (2013). MicroRNAs and the butterfly effect. Cell Cycle 12, 707-708.
17. Dorn GW 2nd, Matkovich SJ, Eschenbacher WH & Zhang Y (2012). A human 3' miR-499 mutation alters cardiac mRNA targeting and function. Circ Res 110, 958-967.
18. Dorn GW 2nd, Robbins J & Sugden PH (2003). Phenotyping hypertrophy: eschew obfuscation. Circ Res 92, 1171-1175.
19. Eitel I, Adams V, Dieterich P, Fuernau G, de Waha S, Desch S, Schuler G & Thiele H.(2012). Relation of circulating microRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am Heart J 164, 706-714.
20. Feldman AM, Weinberg EO, Ray PE & Lorell BH (1993). Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 73, 184-192.
21. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE & Mello CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
22. Geisler S & Coller J (2013). RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 14, 699-712.
23. Greenberg B, Yaroshinsky A, Zsebo KM, Butler J, Felker GM, Voors AA, Rudy JJ, Wagner K & Hajjar RJ (2014). Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail 2, 84-92.
24. Grote P, Wittler L, Hendrix D, Koch F, Wahrisch S, Beisaw A, Macura K, Blass G, Kellis M, Werber M & Herrmann BG (2013). The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell 24, 206-214.
25. Guo JU, Agarwal V, Guo H & Bartel DP (2014). Expanded identification and characterization of mammalian circular RNAs. Genome Biol 15, 409.
26. Haas J, Frese KS, Park YJ, Keller A, Vogel B, Lindroth AM, Weichenhan D, Franke J, Fischer S, Bauer A, Marquart S, Sedaghat-Hamedani F, Kayvanpour E, Kohler D, Wolf NM, Hassel S, Nietsch R, Wieland T, Ehlermann P, Schultz JH, Dosch A, Mereles D, Hardt S, Backs J, Hoheisel JD, Plass C, Katus HA & Meder B (2013). Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med 5, 413-429.
27. Haberland M, Montgomery RL & Olson EN (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10, 32-42.
28. Han P, Li W, Lin CH, Yang J, Shang C, Nurnberg ST, Jin KK, Xu W, Lin CY, Lin CJ, Xiong Y, Chien HC, Zhou B, Ashley E, Bernstein D, Chen PS, Chen HS, Quertermous T & Chang CP (2014). A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514, 102-106.
29. Hausser J & Zavolan M (2014). Identification and consequences of miRNA-target interactions - beyond repression of gene expression. Nat Rev Genet 15, 599-612.
30. Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA & Dimmeler S (2012). Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 14, 249-256.
31. Horvath S (2013). DNA methylation age of human tissues and cell types. Genome Biol 14, R115.
32. Hu Y, Matkovich SJ, Hecker PA, Zhang Y, Edwards JR & Dorn GW 2nd (2012). Epitranscriptional orchestration of genetic reprogramming is an emergent property of stress-regulated cardiac microRNAs. Proc Natl Acad Sci USA 109, 19864-19869.
33. Huntzinger E & Izaurralde E (2011). Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12, 99-110.
34. Izumo S, Nadal-Ginard B & Mahdavi V (1988). Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 85, 339-343.
35. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K, Zhang Z, Rosenberg P, Mirotsou M & Dzau VJ (2012). MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 110, 1465-1473.
36. 2+-ATPase in patients with advanced heart failure. Circulation 124, 304-313.
37. Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML, Ding H, Butty VL, Torrey L, Haas S, Abo R, Tabebordbar M, Lee RT, Burge CB & Boyer LA (2013). Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 152, 570-583.
38. Lee HC, Yang CW, Chen CY & Au LC (2011). Single point mutation of microRNA may cause butterfly effect on alteration of global gene expression. Biochem Biophys Res Commun 404, 1065-1069.
39. Lee JT (2012). Epigenetic regulation by long noncoding RNAs. Science 338, 1435-1439.
40. Matkovich SJ (2014). MicroRNAs in the stressed heart: Sorting the signal from the noise. Cells 3, 778-801.
41. Matkovich SJ, Edwards JR, Grossenheider TC, de Guzman Strong C & Dorn GW (2014). Epigenetic coordination of embryonic heart transcription by dynamically regulated long noncoding RNAs. Proc Natl Acad Sci USA 111, 12264-12269.
42. Matkovich SJ, Hu Y & Dorn GW 2nd (2013). Regulation of cardiac microRNAs by cardiac microRNAs. Circ Res 113, 62-71.
43. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE & (2012). Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res 111, 521-531.
44. Matkovich SJ, Van Booven DJ, Eschenbacher WH & Dorn GW (2011). RISC RNA sequencing for context-specific identification of in vivo microRNA targets. Circ Res 108, 18-26.
45. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies KB & Dorn GW (2009). Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 119, 1263-1271.
46. Mohammad F, Mondal T, Guseva N, Pandey GK & Kanduri C (2010). Kcnq1ot1 noncoding RNA mediates transcriptional gene silencing by interacting with Dnmt1. Development 137, 2493-2499.
47. Moore MJ, Zhang C, Gantman EC, Mele A, Darnell JC & Darnell RB (2014). Mapping Argonaute and conventional RNA-binding protein interactions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis. Nat Protoc 9, 263-293.
48. Ng K, Pullirsch D, Leeb M & Wutz A (2007). Xist and the order of silencing. EMBO Rep 8, 34-39.
49. Olson EN (2006). Gene regulatory networks in the evolution and development of the heart. Science 313, 1922-1927.
50. Ounzain S, Micheletti R, Beckmann T, Schroen B, Alexanian M, Pezzuto I, Crippa S, Nemir M, Sarre A, Johnson R, Dauvillier J, Burdet F, Ibberson M, Guigo R, Xenarios I, Heymans S & Pedrazzini T (2014). Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. Eur Heart J (in press; DOI: http://dx.doi.org/10.1093/eurheartj/ehu180).
51. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, Nagano T, Mancini-Dinardo D & Kanduri C (2008). Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell 32, 232-246.
52. Parker TG, Packer SE & Schneider MD (1990). Peptide growth factors can provoke 'fetal' contractile protein gene expression in rat cardiac myocytes. J Clin Invest 85, 507-514.
53. Schonrock N, Harvey RP & Mattick JS (2012). Long noncoding RNAs in cardiac development and pathophysiology. Circ Res 111, 1349-1362.
54. Seeger FH, Zeiher AM & Dimmeler S (2013). MicroRNAs in stem cell function and regenerative therapy of the heart. Arterioscler Thromb Vasc Biol 33, 1739-1746.
55. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE & Pinto YM (2010). MiR423-5p as a circulating biomarker for heart failure. Circ Res 106, 1035-1039.
56. Vallaster M, Vallaster CD & Wu SM (2012). Epigenetic mechanisms in cardiac development and disease. Acta Biochim Biophys Sin (Shanghai) 44, 92-102.
57. van Rooij E & Olson EN (2007). MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117, 2369-2376.
58. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, Kelm RJ & Olson EN (2009). A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 17, 662-673.
59. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J & Olson EN (2007). Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579.
60. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD & Remaley AT (2011). MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13, 423-433.
61. Viereck J, Bang C, Foinquinos A & Thum T (2014). Regulatory RNAs and paracrine networks in the heart. Cardiovasc Res 102, 290-301.
62. Yang KC, Yamada KA, Patel AY, Topkara VK, George I, Cheema FH, Ewald GA, Mann DL & Nerbonne JM (2014). Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 129, 1009-1021.
63. Yao Y, Du J, Cao X, Wang Y, Huang Y, Hu S & Zheng Z (2014). Plasma levels of microRNA-499 provide an early indication of perioperative myocardial infarction in coronary artery bypass graft patients. PLoS One 9, e104618.
64. Zhao Y, Samal E & Srivastava D (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436, 214-220.
65. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D & Ferrara N (2012). Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 31, 3513-3523.